Evaluation of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: a prospective multicenter single-arm interventional study.
- Author:
Xiao-Yun YIN
1
;
Yun-Mei ZHANG
2
;
Ai-Dong SHEN
3
;
Jing-Ping WANG
4
;
Zhe-Xun LIAN
5
;
Yi-Bing SHAO
6
;
Wen-Qi ZHANG
7
;
Shu-Ying ZHANG
8
;
Yang ZHENG
9
;
Kang CHENG
10
;
Biao XU
11
;
Cheng-Xing SHEN
12
;
Rong-Chong HUANG
13
;
Jin-Cheng GUO
14
;
Guo-Sheng FU
15
;
Dong-Kai SHAN
1
;
Dan-Dan LI
1
;
Yun-Dai CHEN
1
Author Information
- Publication Type:Journal Article
- From: Journal of Geriatric Cardiology 2023;20(4):256-267
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evaluate the feasibility and tolerability of metoprolol standard dosing pathway (MSDP) in Chinese patients with acute coronary syndrome (ACS).
METHODS:In this multicenter, prospective, open label, single-arm and interventional study that was conducted from February 2018 to April 2019 in fifteen Chinese hospitals. A total of 998 hospitalized patients aged ≥ 18 years and diagnosed with ACS were included. The MSDP was applied to all eligible ACS patients based on the standard treatment recommended by international guidelines. The primary endpoint was the percentage of patients achieving the target dose at discharge (V2). The secondary endpoints included the heart rate and blood pressure at V2 and four weeks after discharge (V4), and percentage of patients experiencing bradycardia (heart rate < 50 beats/min), hypotension (blood pressure < 90/60 mmHg) and transient cardiac dysfunction at V2 and V4.
RESULTS:Of the 998 patients, 29.46% of patients achieved the target dose (≥ 95 mg/d) at V2. The total population was divided into two groups: target group (patients achieving the target dose at V2) and non-target group (patients not achieving the target dose at V2). There was significant difference in the reduction of heart rate from baseline to discharge in the two groups (-4.97 ± 11.90 beats/min vs. -2.70 ± 9.47 beats/min, P = 0.034). There was no significant difference in the proportion of bradycardia that occurred in the two groups at V2 (0 vs. 0, P = 1.000) and V4 (0.81% vs. 0.33%, P = 0.715). There was no significant difference in the proportion of hypotension between the two groups at V2 (0.004% vs. 0.004%, P = 1.000) and V4 (0 vs. 0.005%, P = 0.560). No transient cardiac dysfunction occurred in two groups during the study. A total of five adverse events (1.70%) and one serious adverse event (0.34%) were related to the pathway in target group.
CONCLUSIONS:In Chinese ACS patients, the feasibility and tolerability of the MSDP have been proved to be acceptable.
